Access to hematopoietic stem-cell transplantation in India.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Multimodal melphalan delivery: improved safety and outcomes with autologous myeloma transplant in India.Public health action · 2026
   Article
2. A Retrospective Study of Rabbit Anti-T Lymphocyte Globulin (rATLG) as a Second-Line Therapy in Transplant-Ineligible Severe Aplastic Anemia Patients.Cureus · 2025
   Article
3. Advancing Hematopoietic Stem Cell Transplantation (HSCT) in Africa: A Pathway to Curing Hematological Disorders.Health science reports · 2025
   Article
4. Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries.Biomedicines · 2025
   Review
5. Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.Annals of hematology · 2024
   Review
6. Real-World Challenges of Haplo-Identical Hematopoietic Stem Cell Transplant in a Developing Country: A Single Center Experience.Cureus · 2024
   Article
7. Comparable outcomes with low-dose and standard-dose horse anti-thymocyte globulin in the treatment of severe aplastic anemia.Blood research · 2024
   Article
8. Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.International journal of hematology · 2024
   Article
9. Review of the unmet medical need for vaccination in adults with immunocompromising conditions: An Indian perspective.Human vaccines & immunotherapeutics · 2023
   Review
10. Commentary on: Aqueous-deficient dry eye and systemic disease - More than meets the eye.Indian journal of ophthalmology · 2023
    Article
11. Cost of HSCT in a Tertiary Care Public Sector Hospital in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
12. Haploidentical Hematopoietic Stem Cell Transplantation in Leukemia's: Experience from a Cancer Center in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2021
    Article
13. Commentary: Ocular graft versus host disease: Need for multidisciplinary care.Indian journal of ophthalmology · 2021
    Article
14. Development of a clinical hematology and stem cell transplantation program to provide state-of-the-art and cost-effective treatment to patients: a successful collaboration between a medical college in India and a leading medical university in the United States.Blood advances · 2019
    Article
15. Progress in multiple myeloma.The Indian journal of medical research · 2019
    Article
16. Bone marrow transplant: A two-decade single centre hematology experience.Medical journal, Armed Forces India
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as